Marche-en-Famenne, Belgium, November 2nd, 2021
Bioxodes, a clinical-stage biotechnology company announces today the appointment of Dr. Warrinnier as Chief Medical Officer. Dr. Warrinnier will oversee all the company’s activities related to the global clinical strategic development of Ir-CPI, a novel therapeutic solution for patients with thrombo-inflammatory diseases, as well as additional pipeline candidates. Dr. Warrinnier has more than 20 years’ experience in the pharmaceutical industry and will strengthen the company’s management team.
“Dr. Warrinnier’s distinguished career in pharmaceutical industry makes him an ideal candidate to lead our clinical team and oversee the development of innovative therapies to prevent thrombotic and inflammatory diseases for which there is an unmet medical need” declared Edmond Godfroid, Chief Executive Officer of Bioxodes.
“I look forward to joining this dynamic management team and leading the next phase of clinical development for Ir-CPI, our drug candidate that targets Factors XIa, XIIa and neutrophils for the treatment of thrombo-inflammatory diseases, as we prepare it to enter the Phase IIa clinical trial” said Dr. Warrinnier. “I believe that Bioxodes’ scientific vision and innovative approach will drive the continued success of the company, as we work together to deliver groundbreaking therapies for medical unmet needs”.
Dr. Warrinnier joins Bioxodes following a leadership tenure at Roche Belgium where he held various senior leadership positions such as Medical Director. In this position, he led a team of 70+ across Clinical Operations, Medical Affairs and Medical Information, Drug Safety and Regulatory Affairs. He developed and supported affiliate and global clinical studies in different therapeutic areas, maintaining Belgium’s top spot in clinical trials per capita in the world. He delivered strategic expertise and advice for market access solutions in Belgium across different therapeutic areas, including oncology, hematology, neurology, immunology, and hemophilia. In addition to receiving his medical degree from the KU Leuven in Belgium, Dr. Warrinnier followed Business school programs from London Business School and Harvard Business School.
Bioxodes is dedicated to the development of novel therapeutics in the prevention and treatment of thrombotic and inflammatory diseases. Since its setup in 2013, Bioxodes has been developing its lead program based on the Ir-CPI molecule. Ir-CPI is the first candidate in a novel class of therapeutic solutions for patients with thrombo-inflammatory diseases and potentially the first antithrombotic injectable molecule with limited risk of bleeding. The company has so far successfully raised €22.1M from Belgian investment funds and Business Angels, including €8.5M of non-dilutive funding from the Walloon Region. Importantly, Bioxodes owns issued and pending patents related to Ir-CPI in the EU and US.
Clinical practice shows that the main unmet need in the field of thrombosis prevention is the availability of an antithrombotic therapy without bleeding risk. Thanks to its unique mode of action targeting both coagulation Factors XIIa and XIa (1), Ir-CPI is a promising alternative to current anticoagulants since deficiencies in these factors protect against thrombosis without causing spontaneous bleeding. Indeed, Ir-CPI has been proven to be as efficient as unfractionated heparin, the current gold standard, but without any bleeding risk, as shown in preclinical large animal models including a cardiopulmonary bypass (2). Finally, Bioxodes has successfully completed the active phase of its First-in-Human study performed in human volunteers providing favourable data to support the next clinical evaluation in thrombo-inflammatory disease.
1. Demoulin, S., E. Godfroid, and C. Hermans, Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection. J Thromb Haemost, 2021. 19(2): p. 323-329.
2. Pireaux, V., et al., Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. J Am Coll Cardiol, 2019. 74(17): p. 2178-2189.